Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

107 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
New-onset inflammatory bowel diseases among IL-17 inhibitor-treated patients: results from the case-control MISSIL study.
Letarouilly JG, Pham T, Pierache A, Acquacalda É, Banneville B, Barbarot S, Baudart P, Bauer É, Claudepierre P, Constantin A, Dernis E, Felten R, Gaudin P, Girard C, Gombert B, Goupille P, Guennoc X, Henry-Desailly I, Jullien D, Karimova E, Lanot S, Le Dantec L, Pascart T, Plastaras L, Sultan N, Truchet X, Varin S, Wendling D, Gaboriau L, Staumont-Sallé D, Peyrin-Biroulet L, Flipo RM. Letarouilly JG, et al. Among authors: felten r. Rheumatology (Oxford). 2022 Jul 6;61(7):2848-2855. doi: 10.1093/rheumatology/keab819. Rheumatology (Oxford). 2022. PMID: 34730790
Non-primary Sjogren's Syndrome: Secondary or associated?
Felten R, Meyer A, Gottenberg JE. Felten R, et al. Joint Bone Spine. 2023 Mar;90(2):105502. doi: 10.1016/j.jbspin.2022.105502. Epub 2022 Dec 1. Joint Bone Spine. 2023. PMID: 36464213 No abstract available.
Examining the biological pathways underlying clinical heterogeneity in Sjogren's syndrome: proteomic and network analysis.
Berry JS, Tarn J, Casement J, Duret PM, Scott L, Wood K, Johnsen SJ, Nordmark G, Devauchelle-Pensec V, Seror R, Fisher B, Barone F, Bowman SJ, Bombardieri M, Lendrem D, Felten R, Gottenberg JE, Ng WF. Berry JS, et al. Among authors: felten r. Ann Rheum Dis. 2024 Jan 2;83(1):88-95. doi: 10.1136/ard-2023-224503. Ann Rheum Dis. 2024. PMID: 37657927
Immunomodulators for immunocompromised patients hospitalized for COVID-19: a meta-analysis of randomized controlled trials.
Siempos II, Kalil AC, Belhadi D, Veiga VC, Cavalcanti AB, Branch-Elliman W, Papoutsi E, Gkirgkiris K, Xixi NA, Kotanidou A, Hermine O, Porcher R, Mariette X; CORIMUNO-19 Collaborative Group; DisCoVeRy Study Group; ACTT-2 Study Group; ACTT-3 Study Group. Siempos II, et al. EClinicalMedicine. 2024 Feb 9;69:102472. doi: 10.1016/j.eclinm.2024.102472. eCollection 2024 Mar. EClinicalMedicine. 2024. PMID: 38361992 Free PMC article.
Refining myositis associated with primary Sjögren's syndrome: data from the prospective cohort ASSESS.
Felten R, Giannini M, Nespola B, Lannes B, Levy D, Seror R, Vittecoq O, Hachulla E, Perdriger A, Dieude P, Dubost JJ, Fauchais AL, Le Guern V, Larroche C, Dernis E, Guellec D, Cornec D, Sibilia J, Mariette X, Gottenberg JE, Meyer A. Felten R, et al. Rheumatology (Oxford). 2021 Feb 1;60(2):675-681. doi: 10.1093/rheumatology/keaa257. Rheumatology (Oxford). 2021. PMID: 32780813
Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry.
Strangfeld A, Schäfer M, Gianfrancesco MA, Lawson-Tovey S, Liew JW, Ljung L, Mateus EF, Richez C, Santos MJ, Schmajuk G, Scirè CA, Sirotich E, Sparks JA, Sufka P, Thomas T, Trupin L, Wallace ZS, Al-Adely S, Bachiller-Corral J, Bhana S, Cacoub P, Carmona L, Costello R, Costello W, Gossec L, Grainger R, Hachulla E, Hasseli R, Hausmann JS, Hyrich KL, Izadi Z, Jacobsohn L, Katz P, Kearsley-Fleet L, Robinson PC, Yazdany J, Machado PM; COVID-19 Global Rheumatology Alliance. Strangfeld A, et al. Ann Rheum Dis. 2021 Jul;80(7):930-942. doi: 10.1136/annrheumdis-2020-219498. Epub 2021 Jan 27. Ann Rheum Dis. 2021. PMID: 33504483 Free PMC article.
COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study.
Avouac J, Drumez E, Hachulla E, Seror R, Georgin-Lavialle S, El Mahou S, Pertuiset E, Pham T, Marotte H, Servettaz A, Domont F, Chazerain P, Devaux M, Claudepierre P, Langlois V, Mekinian A, Maria ATJ, Banneville B, Fautrel B, Pouchot J, Thomas T, Flipo RM, Richez C; FAI2R/SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors; FAIR/SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors. Avouac J, et al. Lancet Rheumatol. 2021 Jun;3(6):e419-e426. doi: 10.1016/S2665-9913(21)00059-X. Epub 2021 Mar 25. Lancet Rheumatol. 2021. PMID: 33786454 Free PMC article.
107 results